Urology Times

02/15/2025

Durable antitumor activity continued to be seen with combination treatment with belzutifan (Welireg) plus cabozantinib (Cabometyx) for patients with advanced clear cell renal cell carcinoma, according to the latest data from the phase 3 LITESPARK-003 (NCT03634540) study.

ORR was 70% (95% CI, 55-82) in cohort 1 compared with 31% (95% CI, 19-45) in cohort 2.

02/15/2025

Don't miss out! Betty Wang, MD, of Cleveland Clinic is taking over our X (Twitter) account for the last day of ! Stay tuned for her insights on some of the biggest kidney cancer data presented at the meeting. Tune in!

🔗: https://x.com/UrologyTimes

02/15/2025

Additional data from the phase 3 NIAGARA trial (NCT03732677) bolster the safety and efficacy of perioperative durvalumab (Imfinzi) plus neoadjuvant chemotherapy followed by radical cystectomy and adjuvant chemotherapyin patients with cisplatin-eligible muscle-invasive bladder cancer.

The pCR was 37.3% (95% CI, 33.2-41.6) in the durvalumab arm and 27.5% (95% CI, 23.8-31.6) in the comparator arm.

02/15/2025

First-line maintenance treatment with avelumab (Bavencio) in patients with advanced urothelial carcinoma is safe and effective in patients with or without diabetes mellitus, according to data from the JAVELIN Bladder 100 study presented at the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium in San Francisco, California.

OS was found to be prolonged with avelumab plus BSC vs BSC alone regardless of diabetes mellitus status.

02/14/2025

Tune in! Laura Bukavina MD, MPH, MSc, is taking over our X (Twitter) account today to share insights on the latest bladder cancer data and session updates from ! Join the conversation ⬇️

X Account: https://x.com/UrologyTimes

02/14/2025

A literature review of nearly 50 studies has underlined the safety and efficacy of radium-223 (Ra-223, Xofigo) treatment for metastatic castration-resistant prostate cancer.

A total of 37 studies included real-world OS as an outcome; in these studies, median real-world OS ranged from 9 months to 23.5 months.

02/13/2025

An individual participant data meta-analysis of androgen receptor pathway inhibitor trials found that these treatments confer clear survival benefits in younger patients with metastatic hormone-sensitive prostate cancer, whereas in older patients, the risks and benefits of each agent need to be carefully considered.

“Looking at our overall results, not surprisingly, we can show a clear benefit of ARPIs on overall survival," says David Fisher, MSc, MA.

02/12/2025

Treatment with UGN-101 was associated with a median duration of response of nearly 4 years among patients with low-grade UTUC who achieved a complete response.

The median duration of response was 47.8 months among patients who achieved an initial complete response.

02/11/2025

Regulatory authorities in Denmark have approved Illuccix, a kit for the preparation of gallium-68 (68Ga) gozetotide (PSMA-11) injection.

Illuccix has been previously approved in the US, Australia, Canada, and Europe.

02/11/2025

Data from a recent survey sheds light on the substantial impact of postpartum urinary incontinence, with 85% of mothers indicating that they experienced frequent bladder leaks.

Overall, 85% of respondents indicating that they experienced frequent bladder leaks.

02/10/2025

The FDA has granted 510(k) clearance to Ibex Prostate Detect, an AI-powered digital pathology tool designed to detect prostatic cancers that may have been overlooked on the first diagnostic assessment.

The software generates heatmaps to help identify prostatic tumors that may have been missed on initial reads.

02/07/2025

"The take-home point from our study of these 92 patients is that in metastatic kidney cancer, there's a high concordance [between] MRD positivity and patients having progressive disease," says Alan Tan, MD.

"The take-home point from our study of these 92 patients is that in metastatic kidney cancer, there's a high concordance [between] MRD positivity and patients having progressive disease," says Alan Tan, MD.

02/07/2025

Data from the pivotal OASIS trial have been published in the Journal of Urology, showing that efficacy of the Revi System for UUI was maintained at 2 years.

At 24 months, 79% of patients experienced a response to therapy, and 56% achieved at least a 75% reduction in UUI episodes.

02/06/2025

All 9 participants who received a neoantigen cancer vaccine for ccRCC remained free of disease recurrence at approximately 3 years following treatment, according to data from a phase 1 study.

At a median follow-up of 40.2 months post-surgery, no patients had experienced a disease recurrence.

02/05/2025

Join Dr. Jose De La Cerda III, MD, and Urology Times® for an Exclusive Clinical Forum on mCRPC at ASCO GU 2025!

Don’t miss out on this insightful discussion with leading experts in the field. Reserve your spot today!

RSVP TODAY: https://bit.ly/4hEVeDX

02/05/2025

The FDA has awarded both an orphan drug designation and a rare pediatric disease designation to ABO-101 for the treatment of primary hyperoxaluria type 1.

A phase 1/2 trial of ABO-101 is expected to launch in the first half of 2025.

02/04/2025

A phase 2 trial has been initiated to explore the combination of opaganib and darolutamide in patients with mCRPC.

The primary end point is 12-month radiographic progression-free survival.

02/04/2025

In recognition of , Urology Times has compiled a list of statistics, trends, and information on the observed benefits of screening for 4 different forms of urologic cancer.

A list of facts and trends to know about the current landscape of urologic cancer management and research in the US.